OSE Immunotherapeutics Responds to Court Decision

On September 23, 2025, OSE Immunotherapeutics SA acknowledged the decision of the Nantes Commercial Court, which dismissed the company's claims regarding a concerted action by a group of minority shareholders. The firm's Board of Directors, prioritizing strategic focus, opted not to appeal the ruling, despite believing in their initial stance.

Ahead of the upcoming General Meeting, an error related to free share voting rights was identified and corrected. The Board contends that this error stemmed from a misjudgment by a corporate advisor, not from any fraudulent intent. A corrective press release will be issued shortly.

OSE Immunotherapeutics is committed to transparency and ensuring proper proceedings at the General Meeting on September 30, 2025, maintaining respect for all shareholder rights.